• AMAL Therapeutics Finalises €29 Million (CHF 33.2 Million) Series B Round b3cnewswire
    November 12, 2018
    The Company will use the funds to progress its lead vaccine (ATP128) toward clinical development and proof-of-concept in colorectal cancer, a leading cause of mortality and a significant market opportunity (€9.6 billion by 2025). The clinical trial is exp
  • Syncona powers gene therapy startup Freeline to £88M B round fiercebiotech
    June 25, 2018
    Syncona has dialed up its bet on gene therapy startup Freeline Therapeutics. The life science investor committed £85 million ($112 million) to Freeline’s £88 million series B round, thereby maintaining a big stake in a biotech that is working to redefine
PharmaSources Customer Service